<html>
  <head>
    <title>
</title></head>
  <body bgcolor="#ffffff">
    <div><br>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">UNITED
        STATES</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">SECURITIES
        AND EXCHANGE COMMISSION</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">WASHINGTON,
        D.C. 20549</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><strong>FORM
        8-K</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">CURRENT
        REPORT</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">PURSUANT
        TO SECTION 13 OR 15(</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">d</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">)
        OF</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">THE
        SECURITIES EXCHANGE ACT OF 1934</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Date
        of
        Report (Date of earliest event reported): October 18, 2005</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><strong>VioQuest
        Pharmaceuticals, Inc.</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Exact
        name of registrant as specified in its charter)</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div align="center">
        <table bgcolor="#ffffff" cellpadding="0" cellspacing="0" width="100%">

            <tr bgcolor="#ffffff">
              <td width="33.33%">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;<strong><font size="2">Delaware</font></strong></div>
              </td>
              <td width="33.33%">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>000-16686</strong></font></div>
              </td>
              <td width="33.33%">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;<strong><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">58-1486040
                  </font></strong></div>
              </td>
            </tr>
            <tr bgcolor="#ffffff">
              <td width="33.33%">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;<font size="2">(State
                  or other jurisdiction
                  of</font></div>
              </td>
              <td width="33.33%">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;<font size="2">(Commission
                  File Number)</font></div>
              </td>
              <td width="33.33%">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;<font size="2">(IRS
                  Employer</font></div>
              </td>
            </tr>
            <tr bgcolor="#ffffff">
              <td width="33.33%">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;<font size="2">incorporation)</font></div>
              </td>
              <td width="33.33%">&#160;</td>
              <td width="33.33%">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;<font size="2">Identification
                  No.)</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div align="center">
        <table bgcolor="#ffffff" cellpadding="0" cellspacing="0" width="100%">

            <tr bgcolor="#ffffff">
              <td width="33.33%">&#160;</td>
              <td width="33.33%">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;<strong><font size="2">7
                  Deer Park Drive, Suite
                  E</font></strong></div>
              </td>
              <td width="33.33%">&#160;</td>
            </tr>
            <tr bgcolor="#ffffff">
              <td width="33.33%">&#160;</td>
              <td width="33.33%">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;<strong><font size="2">Monmouth
                  Junction, NJ
                  08852</font></strong></div>
              </td>
              <td width="33.33%">&#160;</td>
            </tr>
            <tr bgcolor="#ffffff">
              <td width="33.33%">&#160;</td>
              <td width="33.33%">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;<font size="2">(Address
                  of principal executive
                  offices)</font></div>
              </td>
              <td width="33.33%">&#160;</td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br>
        <div align="center">
          <table bgcolor="#ffffff" cellpadding="0" cellspacing="0" width="100%">

              <tr bgcolor="#ffffff">
                <td width="30%">&#160;</td>
                <td width="39%">
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;<strong><font size="2">(732)
                    274-0399</font></strong></div>
                </td>
                <td width="30%">&#160;</td>
              </tr>
              <tr bgcolor="#ffffff">
                <td width="30%">&#160;</td>
                <td width="39%">
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;<font size="2">(Registrant's
                    telephone number, including
                    area code) </font></div>
                </td>
                <td width="30%">&#160;</td>
              </tr>
              <tr bgcolor="#ffffff">
                <td width="30%">&#160;</td>
                <td width="39%">&#160;</td>
                <td width="30%">&#160;</td>
              </tr>

          </table>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Former
        name or former address, if changed since last report)</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Check
        the
        appropriate box below if the Form 8-K filing is intended to simultaneously
        satisfy the filing obligation of the registrant under any of the following
        provisions:</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div>
        <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">

            <tr valign="top" style="LINE-HEIGHT: 1.25">
              <td align="left" style="WIDTH: 9pt"><font style="DISPLAY: inline; FONT-FAMILY: Wingdings">o</font></td>
              <td align="left">
                <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;Written
                  communications pursuant to Rule 425 under the Securities Act (17
                  CFR
                  230.425)</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div>
        <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">

            <tr valign="top" style="LINE-HEIGHT: 1.25">
              <td align="left" style="WIDTH: 9pt"><font style="FONT-FAMILY: Wingdings">o</font></td>
              <td align="left">
                <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;Soliciting
                  material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
                  240.14a-12)</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div>
        <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">

            <tr valign="top" style="LINE-HEIGHT: 1.25">
              <td align="left" style="WIDTH: 9pt"><font style="FONT-FAMILY: Wingdings">o</font></td>
              <td align="left">
                <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;Pre-commencement
                  communications pursuant to Rule 14d-2(b) under the Exchange Act
                  (17 CFR
                  240.14d-2(b))</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div>
        <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">

            <tr valign="top" style="LINE-HEIGHT: 1.25">
              <td align="left" style="WIDTH: 9pt"><font style="FONT-FAMILY: Wingdings">o</font></td>
              <td align="left">
                <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;Pre-commencement
                  communications pursuant to Rule 13e-4(c) under the Exchange Act
                  (17 CFR
                  240.13e-4(c))</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="left">
          </div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
          </div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="right">
          </div>
        </div>
      </div><br>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Item
        1.01.</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Entry
        into a Material Definitive Agreement.</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(a)
        </font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On
        July
        1, 2005, VioQuest Pharmaceuticals, Inc. (the &#8220;Company&#8221;) entered into an
        Agreement and Plan of Merger, as amended&#160;(the &#8220;Merger Agreement&#8221;), with
        Greenwich Therapeutics, Inc., a Delaware corporation (&#8220;Greenwich&#8221;), and VQ
        Acquisition Corp., a Delaware corporation and wholly-owned subsidiary of
        the
        Company (&#8220;VAC&#8221;). Greenwich is a privately-held, New York-based biotechnology
        company, which owns exclusive license rights to two anti-cancer agents -
        sodium
        stibogluconate (SSG) and triciribine (TCN-P). The Merger Agreement provided
        that
        VAC would merge with and into Greenwich, with Greenwich remaining as the
        surviving corporation and a wholly-owned subsidiary of the Company (the
&#8220;Merger&#8221;). The Merger was completed October 18, 2005. In consideration for their
        shares of Greenwich capital stock and in accordance with the Merger Agreement,
        the stockholders of Greenwich received an aggregate of 17,128,790 shares
        of the
        Company&#8217;s common stock in the Merger. In addition to such common shares, the
        Company also issued to the Greenwich stockholders five-year warrants to purchase
        an aggregate of 4,000,000 shares of the Company&#8217;s common stock at an exercise
        price of $1.41 per share. One-half of the shares and warrants issued to
        Greenwich&#8217;s stockholders have been placed in escrow in accordance with the terms
        of the Escrow Agreement (discussed under Item 1.01(b) below) and will be
        released incrementally upon the achievement of certain milestones relating
        to
        the clinical development of Greenwich&#8217;s two product candidates. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">At
        the
        time of the Merger, Greenwich had outstanding indebtedness of approximately
        $794,000 resulting from a promissory note issued to Paramount BioCapital
        Investments, LLC, which is owned and controlled by Dr. Lindsay Rosenwald.
        In
        accordance with the Merger Agreement, the note was amended (the &#8220;Amendment&#8221;) at
        the time of the Merger to provide that the Company would assume the outstanding
        indebtedness under the note and that (i) one-third of the outstanding
        indebtedness was payable at such time as the Company raises at least $5 million
        in new financing (the &#8220;Offering&#8221;), (ii) one-third of the outstanding
        indebtedness was payable at such time as the Company raises at least $10
        million
        in new financing (including the amounts raised in the Offering referenced
        in
        clause (i)), and (iii) one-third of the outstanding indebtedness would convert
        into shares of the Company&#8217;s common stock at the closing of the Offering.
</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Several
        of Greenwich&#8217;s former stockholders are directors or significant stockholders of
        the Company. Dr. Rosenwald and various trusts established for the benefit
        of Dr.
        Rosenwald and members of his immediate family collectively beneficially owned
        approximately 48 percent of Greenwich&#8217;s common stock and, immediately prior to
        the Merger, beneficially owned approximately 16 percent of our common stock.
        In
        addition, Stephen C. Rocamboli and Michael Weiser, each of whom is a member
        of
        the Company&#8217;s board of directors, collectively owned approximately 11 percent of
        Greenwich&#8217;s outstanding common stock. Mr. Rocamboli and Dr. Weiser are also
        employed by Paramount BioCapital, Inc., an entity owned and controlled by
        Dr.
        Rosenwald. As a result of such relationships with Greenwich, both Mr. Rocamboli
        and Dr. Weiser did not attend or otherwise participate in any meetings of
        the
        Company&#8217;s Board of Directors relating to the Merger Agreement. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">A
        press
        release dated October 19, 2005 announcing the Merger is attached to this
        Form
        8-K as Exhibit 99.1 and incorporated herein by reference.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(b)</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
        accordance with the terms of the Merger Agreement, on October 18, 2005, the
        Company entered into an Escrow Agreement with Greenwich, J. Jay Lobell and
        U.S.
        Bank National Association, a national banking association (the &#8220;Escrow Agent&#8221;),
        pursuant to which one-half of the shares and warrants issued to Greenwich&#8217;s
        former stockholders were placed in escrow with the Escrow Agent and will
        be
        released incrementally upon the achievement of certain milestones relating
        to
        the clinical development of Greenwich&#8217;s two former product
        candidates.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(c)</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
        accordance with the terms of the Merger Agreement, on October 18, 2005, the
        Company entered into a Registration Rights Agreement with Greenwich&#8217;s former
        stockholders pursuant to which the Company agreed to provide such stockholders
        with piggy-back registration rights with respect to the shares and warrants
        issued to them by the Company. Under the terms of the Registration Rights
        Agreement, the stockholders of Greenwich agreed not to sell or transfer their
        shares for a period of one year from the date of the agreement.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(d)</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As
        disclosed under Item 3.02(c) below, </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">on
        October 18, 2005, the Company entered into a series of subscription agreements
        with certain investors for the sale of an aggregate of 4,471,975 shares of
        its
        common stock and 5-year warrants to purchase an aggregate of 4,471,975 shares
        of
        its common stock. The disclosures set forth in paragraph (c) of Item 3.02
        are
        hereby incorporated by reference into this Item 1.01. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="left">
          </div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
          </div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="right">
          </div>
        </div>
        <div>&#160;</div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Item
        2.01.</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Completion
        of Acquisition or Disposition of Assets.</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
        disclosures set forth in paragraph (a) of Item 1.01 are hereby incorporated
        by
        reference into this Item 2.01.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Item
        3.02 Unregistered Sales of Equity Securities.</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(a)</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As
        disclosed under Item 1.01 above, in connection with the Merger, the Company
        issued an aggregate of </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">17,128,790
        </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">shares
        of
        its common stock and warrants to purchase an additional 4,000,000 shares
        of
        common stock to the former holders of Greenwich common stock. The Company
        relied
        on the exemption from federal registration under Section&#160;4(2) of the
        Securities Act of 1933, as amended (the&#160;&#8220;Securities Act&#8221;),&#160;and Rule
        506 promulgated thereunder, based on its belief that the issuance of such
        securities did not involve a public offering, as there were fewer than 35
        &#8220;non-accredited&#8221; investors, all of whom, either alone or through a purchaser
        representative, had such knowledge and experience in financial and business
        matters so that each was capable of evaluating the risks of the
        investment.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(b)</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
        to the terms of the Amendment disclosed under Item 1.01 above, the Company
        issued 392,830 shares of its common stock at a per-share price of $0.75 to
        Paramount BioCapital Investments, LLC in satisfaction of approximately $295,000
        of the indebtedness due under the Amendment. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(c)</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Additionally,
        on October 18, 2005, the Company sold 11,179,975 shares (the &#8220;Shares&#8221;) of its
        common stock at a price of $0.75 per share resulting in gross proceeds of
        approximately $8.38 million. In addition to the shares of common stock, the
        investors also received 5-year warrants (the &#8220;Warrants&#8221;) to purchase an
        aggregate of 4,471,975 shares at an exercise price of $1.00 per share. In
        connection with the private placement, the Company paid an aggregate of
        approximately $587,000 in commissions to Paramount BioCapital, Inc., which
        served as the placement agent in connection with the offering, together with
        an
        accountable expense allowance of $50,000, and issued 5-year warrants to purchase
        an aggregate of 1,117,997 shares of common stock at a price of $1.00 per
        share.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
        common shares and warrants were sold to seventy-six investors, each of which
        the
        Company reasonably believes is an &#8220;accredited investor,&#8221; as defined under Rule
        502 of the Securities Act of 1933, and no means of general solicitation or
        advertising was used in connection with the offering. Accordingly, the Company
        relied on the exemptions from the registration requirements of the Securities
        Act provided by Section 4(2) and Rule 506.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
        connection with the private placement, the Company agreed to file, within
        30
        days of the closing, a registration statement under the Securities Act covering
        the resale of the Shares and the shares issuable upon exercise of the Warrants.
        The Company further agreed to cause such registration statement to be declared
        effective by the Commission within 120 days following the closing. In the
        event
        the Company fails to meet such 30-day or 120-day deadlines, it is required
        to
        pay to each investor a cash penalty of 1 percent of the amount of such
        investor&#8217;s investment for each monthly period (or portion thereof) in which the
        Company is not in compliance with its registration obligations.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Item
        9.01 </strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Financial
        Statements and Exhibits.</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div align="center">
        <table bgcolor="#ffffff" cellpadding="0" cellspacing="0" width="100%">

            <tr bgcolor="#ffffff">
              <td width="5%">&#160;</td>
              <td width="5%"><font size="2">(a)</font></td>
              <td width="90%"><font size="2">Financial Statements of Business
                Acquired.</font></td>
            </tr>
            <tr bgcolor="#ffffff">
              <td width="5%">&#160;</td>
              <td width="5%">&#160;</td>
              <td width="90%">&#160;</td>
            </tr>
            <tr bgcolor="#ffffff">
              <td width="5%">&#160;</td>
              <td width="5%">&#160;</td>
              <td width="90%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As
                  a result of its acquisition of Greenwich described in Item 1.01,
                  the
                  Company will file the financial statements required by Item 9.01on
                  or
                  before January 3, 2006.</font></div>
              </td>
            </tr>
            <tr bgcolor="#ffffff">
              <td width="5%">&#160;</td>
              <td width="5%">&#160;</td>
              <td width="90%">&#160;</td>
            </tr>
            <tr bgcolor="#ffffff">
              <td width="5%">&#160;</td>
              <td width="5%"><font size="2">(b)</font>&#160;</td>
              <td width="90%"><font size="2">Pro Forma Financial
                Information.</font>&#160;</td>
            </tr>
            <tr bgcolor="#ffffff">
              <td width="5%">&#160;</td>
              <td width="5%">&#160;</td>
              <td width="90%">&#160;</td>
            </tr>
            <tr bgcolor="#ffffff">
              <td width="5%">&#160;</td>
              <td width="5%">&#160;</td>
              <td width="90%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As
                  a result of its acquisition of Greenwich described in Item 1.01,
                  the
                  Company will file the pro forma financial information required
                  by Item
                  9.01 on or before January 3, 2006.</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div align="center">&#160;</div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="left">
          </div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
          </div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="right">
          </div>
        </div>
        <div>&#160;</div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
        <div align="center">
          <table bgcolor="#ffffff" cellpadding="0" cellspacing="0" width="100%">

              <tr bgcolor="#ffffff">
                <td width="5%">&#160;</td>
                <td width="5%"><font size="2">(c)</font></td>
                <td width="90%"><em><font size="2">Exhibits.</font></em>&#160;</td>
              </tr>
              <tr bgcolor="#ffffff">
                <td width="5%">&#160;</td>
                <td width="5%">&#160;</td>
                <td width="90%">&#160;</td>
              </tr>
              <tr bgcolor="#ffffff">
                <td width="5%">&#160;</td>
                <td width="5%"><font size="2">&#160;99.1</font></td>
                <td width="90%"><font size="2">Press Release dated October 19,
                  2005.</font>&#160;</td>
              </tr>
              <tr bgcolor="#ffffff">
                <td width="5%">&#160;</td>
                <td width="5%">&#160;</td>
                <td width="90%">&#160;</td>
              </tr>
              <tr bgcolor="#ffffff">
                <td width="5%">&#160;</td>
                <td width="5%">&#160;</td>
                <td width="90%">&#160;</td>
              </tr>

          </table>
        </div>
        <div align="center">&#160;</div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>SIGNATURE</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
        to the requirements of the Securities Exchange Act of 1934, the Registrant
        has
        duly caused this report to be signed on its behalf by the undersigned hereunto
        duly authorized.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">
        <table align="center" bgcolor="#ffffff" border="0" cellpadding="0" cellspacing="0" width="100%">

            <tr valign="top" bgcolor="#ffffff">
              <td width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
              <td width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
              <td width="49%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
            </tr>
            <tr valign="top" bgcolor="#ffffff">
              <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
              <td colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>VIOQUEST
                PHARMACEUTICALS, INC.</u></strong></font></td>
            </tr>
            <tr valign="top" bgcolor="#ffffff">
              <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;<br>&#160;</font></td>
              <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;<br>&#160;</font></td>
              <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;<br>&#160;</font></td>
            </tr>
            <tr valign="top" bgcolor="#ffffff">
              <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Date:&#160;October
                24, 2005</font></td>
              <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">By:&#160;&#160;</font></td>
              <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">/s/&#160;Brian
                Lenz</font></td>
            </tr>
            <tr valign="top" bgcolor="#ffffff">
              <td colspan="2"><font style="FONT-FAMILY: Times New Roman" size="1">&#160;</font></td>
              <td align="left">
                <div>
                  <hr style="COLOR: #000000" align="left" noshade size="2" width="80%">
                </div>
                <div><font size="2">Brian Lenz</font></div>
                <div><font size="2">Chief Financial Officer</font></div>
              </td>
            </tr>
            <tr valign="top" bgcolor="#ffffff">
              <td colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
              <td>&#160;</td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="left">
          </div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
          </div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="right">
          </div>
        </div>
      </div><br>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>Exhibit
        Index</u></strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>Ex.
        No.</u></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>Description</u></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">99.1</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Press
        Release dated October 19, 2005</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="left">
          </div>
        </div>
        <div id="PN">
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
          </div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="right">
          </div>
        </div>
      </div>
    </div>
  </body>
</html>
{"company-data": {"conformed-name": "VioQuest Pharmaceuticals, Inc.", "cik": "0000745788", "assigned-sic": "8731", "irs-number": "581486040", "state-of-incorporation": "MN", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-16686", "film-number": "051152805"}, "business-address": {"street1": "7 DEER PARK DRIVE, SUITE E", "street2": "PRINCETON CORPORATE PLAZA", "city": "MONMOUTH JUNCTION", "state": "NJ", "zip": "08852", "phone": "732-274-0399"}, "mail-address": {"street1": "7 DEER PARK DRIVE, SUITE E", "street2": "PRINCETON CORPORATE PLAZA", "city": "MONMOUTH JUNCTION", "state": "NJ", "zip": "08852"}, "former-company": [{"former-conformed-name": "VioQuest Pharmaceuticals", "date-changed": "20041117"}, {"former-conformed-name": "CHIRAL QUEST INC", "date-changed": "20030305"}, {"former-conformed-name": "SURG II INC", "date-changed": "20020605"}]}
UNITED
        STATES
SECURITIES
        AND EXCHANGE COMMISSION
WASHINGTON,
        D.C. 20549
FORM
        8-K
CURRENT
        REPORT
PURSUANT
        TO SECTION 13 OR 15(
d
)
        OF
THE
        SECURITIES EXCHANGE ACT OF 1934
Date
        of
        Report (Date of earliest event reported): October 18, 2005
VioQuest
        Pharmaceuticals, Inc.
(Exact
        name of registrant as specified in its charter)
Delaware
000-16686
58-1486040
(State
                  or other jurisdiction
                  of
(Commission
                  File Number)
(IRS
                  Employer
incorporation)
Identification
                  No.)
7
                  Deer Park Drive, Suite
                  E
Monmouth
                  Junction, NJ
                  08852
(Address
                  of principal executive
                  offices)
(732)
                    274-0399
(Registrant's
                    telephone number, including
                    area code)
(Former
        name or former address, if changed since last report)
Check
        the
        appropriate box below if the Form 8-K filing is intended to simultaneously
        satisfy the filing obligation of the registrant under any of the following
        provisions:
o
Written
                  communications pursuant to Rule 425 under the Securities Act (17
                  CFR
                  230.425)
o
Soliciting
                  material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
                  240.14a-12)
o
Pre-commencement
                  communications pursuant to Rule 14d-2(b) under the Exchange Act
                  (17 CFR
                  240.14d-2(b))
o
Pre-commencement
                  communications pursuant to Rule 13e-4(c) under the Exchange Act
                  (17 CFR
                  240.13e-4(c))
Item
        1.01.
Entry
        into a Material Definitive Agreement.
(a)
On
        July
        1, 2005, VioQuest Pharmaceuticals, Inc. (the "Company") entered into an
        Agreement and Plan of Merger, as amended (the "Merger Agreement"), with
        Greenwich Therapeutics, Inc., a Delaware corporation ("Greenwich"), and VQ
        Acquisition Corp., a Delaware corporation and wholly-owned subsidiary of
        the
        Company ("VAC"). Greenwich is a privately-held, New York-based biotechnology
        company, which owns exclusive license rights to two anti-cancer agents -
        sodium
        stibogluconate (SSG) and triciribine (TCN-P). The Merger Agreement provided
        that
        VAC would merge with and into Greenwich, with Greenwich remaining as the
        surviving corporation and a wholly-owned subsidiary of the Company (the
"Merger"). The Merger was completed October 18, 2005. In consideration for their
        shares of Greenwich capital stock and in accordance with the Merger Agreement,
        the stockholders of Greenwich received an aggregate of 17,128,790 shares
        of the
        Company's common stock in the Merger. In addition to such common shares, the
        Company also issued to the Greenwich stockholders five-year warrants to purchase
        an aggregate of 4,000,000 shares of the Company's common stock at an exercise
        price of $1.41 per share. One-half of the shares and warrants issued to
        Greenwich's stockholders have been placed in escrow in accordance with the terms
        of the Escrow Agreement (discussed under Item 1.01(b) below) and will be
        released incrementally upon the achievement of certain milestones relating
        to
        the clinical development of Greenwich's two product candidates.
At
        the
        time of the Merger, Greenwich had outstanding indebtedness of approximately
        $794,000 resulting from a promissory note issued to Paramount BioCapital
        Investments, LLC, which is owned and controlled by Dr. Lindsay Rosenwald.
        In
        accordance with the Merger Agreement, the note was amended (the "Amendment") at
        the time of the Merger to provide that the Company would assume the outstanding
        indebtedness under the note and that (i) one-third of the outstanding
        indebtedness was payable at such time as the Company raises at least $5 million
        in new financing (the "Offering"), (ii) one-third of the outstanding
        indebtedness was payable at such time as the Company raises at least $10
        million
        in new financing (including the amounts raised in the Offering referenced
        in
        clause (i)), and (iii) one-third of the outstanding indebtedness would convert
        into shares of the Company's common stock at the closing of the Offering.
Several
        of Greenwich's former stockholders are directors or significant stockholders of
        the Company. Dr. Rosenwald and various trusts established for the benefit
        of Dr.
        Rosenwald and members of his immediate family collectively beneficially owned
        approximately 48 percent of Greenwich's common stock and, immediately prior to
        the Merger, beneficially owned approximately 16 percent of our common stock.
        In
        addition, Stephen C. Rocamboli and Michael Weiser, each of whom is a member
        of
        the Company's board of directors, collectively owned approximately 11 percent of
        Greenwich's outstanding common stock. Mr. Rocamboli and Dr. Weiser are also
        employed by Paramount BioCapital, Inc., an entity owned and controlled by
        Dr.
        Rosenwald. As a result of such relationships with Greenwich, both Mr. Rocamboli
        and Dr. Weiser did not attend or otherwise participate in any meetings of
        the
        Company's Board of Directors relating to the Merger Agreement.
A
        press
        release dated October 19, 2005 announcing the Merger is attached to this
        Form
        8-K as Exhibit 99.1 and incorporated herein by reference.
(b)
In
        accordance with the terms of the Merger Agreement, on October 18, 2005, the
        Company entered into an Escrow Agreement with Greenwich, J. Jay Lobell and
        U.S.
        Bank National Association, a national banking association (the "Escrow Agent"),
        pursuant to which one-half of the shares and warrants issued to Greenwich's
        former stockholders were placed in escrow with the Escrow Agent and will
        be
        released incrementally upon the achievement of certain milestones relating
        to
        the clinical development of Greenwich's two former product
        candidates.
(c)
In
        accordance with the terms of the Merger Agreement, on October 18, 2005, the
        Company entered into a Registration Rights Agreement with Greenwich's former
        stockholders pursuant to which the Company agreed to provide such stockholders
        with piggy-back registration rights with respect to the shares and warrants
        issued to them by the Company. Under the terms of the Registration Rights
        Agreement, the stockholders of Greenwich agreed not to sell or transfer their
        shares for a period of one year from the date of the agreement.
(d)
As
        disclosed under Item 3.02(c) below,
on
        October 18, 2005, the Company entered into a series of subscription agreements
        with certain investors for the sale of an aggregate of 4,471,975 shares of
        its
        common stock and 5-year warrants to purchase an aggregate of 4,471,975 shares
        of
        its common stock. The disclosures set forth in paragraph (c) of Item 3.02
        are
        hereby incorporated by reference into this Item 1.01.
Item
        2.01.
Completion
        of Acquisition or Disposition of Assets.
The
        disclosures set forth in paragraph (a) of Item 1.01 are hereby incorporated
        by
        reference into this Item 2.01.
Item
        3.02 Unregistered Sales of Equity Securities.
(a)
As
        disclosed under Item 1.01 above, in connection with the Merger, the Company
        issued an aggregate of
17,128,790
shares
        of
        its common stock and warrants to purchase an additional 4,000,000 shares
        of
        common stock to the former holders of Greenwich common stock. The Company
        relied
        on the exemption from federal registration under Section 4(2) of the
        Securities Act of 1933, as amended (the "Securities Act"), and Rule
        506 promulgated thereunder, based on its belief that the issuance of such
        securities did not involve a public offering, as there were fewer than 35
        "non-accredited" investors, all of whom, either alone or through a purchaser
        representative, had such knowledge and experience in financial and business
        matters so that each was capable of evaluating the risks of the
        investment.
(b)
Pursuant
        to the terms of the Amendment disclosed under Item 1.01 above, the Company
        issued 392,830 shares of its common stock at a per-share price of $0.75 to
        Paramount BioCapital Investments, LLC in satisfaction of approximately $295,000
        of the indebtedness due under the Amendment.
(c)
Additionally,
        on October 18, 2005, the Company sold 11,179,975 shares (the "Shares") of its
        common stock at a price of $0.75 per share resulting in gross proceeds of
        approximately $8.38 million. In addition to the shares of common stock, the
        investors also received 5-year warrants (the "Warrants") to purchase an
        aggregate of 4,471,975 shares at an exercise price of $1.00 per share. In
        connection with the private placement, the Company paid an aggregate of
        approximately $587,000 in commissions to Paramount BioCapital, Inc., which
        served as the placement agent in connection with the offering, together with
        an
        accountable expense allowance of $50,000, and issued 5-year warrants to purchase
        an aggregate of 1,117,997 shares of common stock at a price of $1.00 per
        share.
The
        common shares and warrants were sold to seventy-six investors, each of which
        the
        Company reasonably believes is an "accredited investor," as defined under Rule
        502 of the Securities Act of 1933, and no means of general solicitation or
        advertising was used in connection with the offering. Accordingly, the Company
        relied on the exemptions from the registration requirements of the Securities
        Act provided by Section 4(2) and Rule 506.
In
        connection with the private placement, the Company agreed to file, within
        30
        days of the closing, a registration statement under the Securities Act covering
        the resale of the Shares and the shares issuable upon exercise of the Warrants.
        The Company further agreed to cause such registration statement to be declared
        effective by the Commission within 120 days following the closing. In the
        event
        the Company fails to meet such 30-day or 120-day deadlines, it is required
        to
        pay to each investor a cash penalty of 1 percent of the amount of such
        investor's investment for each monthly period (or portion thereof) in which the
        Company is not in compliance with its registration obligations.
Item
        9.01
Financial
        Statements and Exhibits.
(a)
Financial Statements of Business
                Acquired.
As
                  a result of its acquisition of Greenwich described in Item 1.01,
                  the
                  Company will file the financial statements required by Item 9.01on
                  or
                  before January 3, 2006.
(b)
Pro Forma Financial
                Information.
As
                  a result of its acquisition of Greenwich described in Item 1.01,
                  the
                  Company will file the pro forma financial information required
                  by Item
                  9.01 on or before January 3, 2006.
(c)
Exhibits.
99.1
Press Release dated October 19,
                  2005.
SIGNATURE
Pursuant
        to the requirements of the Securities Exchange Act of 1934, the Registrant
        has
        duly caused this report to be signed on its behalf by the undersigned hereunto
        duly authorized.
VIOQUEST
                PHARMACEUTICALS, INC.
Date: October
                24, 2005
By:
/s/ Brian
                Lenz
Brian Lenz
Chief Financial Officer
Exhibit
        Index
Ex.
        No.
Description
99.1
Press
        Release dated October 19, 2005